ВЛИЯНИЕ ФАКТОРА АНГИОГЕНЕЗА НА МОРФОФУНКЦИОНАЛЬНОЕ СОСТОЯНИЕ МИОКАРДА У КРЫС ПРИ ЭКСПЕРИМЕНТАЛЬНОМ ИНФАРКТЕ МИОКАРДА
Аннотация
Об авторах
А. С. СИСАКЯНАрмения
кафедра пропедевтики внутренних болезней
В. А. ОГАНЯН
Армения
кафедра медицинской биологии и генетики
A. Б. СЕМЕРДЖЯН
Армения
кафедра медицинской биологии и генетики
М. В. ПЕТРОСЯН
Армения
кафедра пропедевтики внутренних болезней
С. А. СИСАКЯН
Армения
кафедра медицинской биологии и генетики
М. А. ГУРЕВИЧ
Россия
Список литературы
1. Bollano E, Tian F, Shao R. Hypoxia –induced myocardial angiogenesis preserves myocardial function after infarction in mouse// Eur. J. Echocardiography, vol 6, suppl Dec 2005 S 34; 279.
2. Dishart K.L., Work L.M., Denby L. et al. Gene therapy for cardiovascular disease// J. Biomed Biotechnol. 2003;2:138–148.
3. Fam N.P., Verma S., Kutryk M. et al. Clinician guide to angiogenesis // Circulation 2003; 108: 2613–2618.
4. Fukuda S. Angiogenic signal triggered by ischemic stress induced myocardial repair in rat during chronic infarction // J. Mol. Cell Cardiology. 2004 Apr 36(4): 547–59.
5. Kleiman N.S., Califf R.M. Results from lateJbreaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of Cardiology // J. Am. Coll. Cardiol. 2000; 36:310–325.
6. Sasaki H., Fukada S. Otani H. et al. Hypoxic preconditioning triggers myocardial angiogenesis: a novel approach to enhance contractile functional reserve in rat with myocardial infarction // J. Mol. Cell. Cardiol. 2002; Mar; 34(3), 335–48.
7. Sisakyan S.A. Investigations of capillary network in the myocardium, skeletal muscles and other organs by modified Gomori’s method for determination of acid phosphatase activity //Cor. Vasa. – 1977. – Vol. 19. – N 4–5. – P. 363–369.
8. Stewart D.J., A phase 2, randomized, multicenter, 26Jweek study to assess the efficacy and safety of BIOBYPASS (AdGV –VEGF 121.10) delivered through minimally invasive surgery vesus maximum medical treatment in patients with severe angina, advanced coronary artery disease, and no options for revascularization // Circulation 2002; 106:2986Ja: Abstract.
9. Symes JF, Losordo DW, Vale PR. Gene therapy with VEGF for inoperable coronary artery disease. Ann Thorac. Surg. 1999; 68; 830–6.
10. Voisine P., Bianchi C., Ruel M. Inhibition of tha cardiac angiogenic response to exogeneos vascular endothelial growth factor // Surgery 2004; 136:2:407–415.
11. Yin R., Feng J, Chen D. Serum levels of VEGF in patients with angina pectoris and acute myocardial infarction // Chin Med. Sci 2000 Dec; 15 (4) 205–9.
12. Yin R., Feng J. Dynamic changes of serum VEGF levels in a rat myocardial infarction model // Chin. Med. Sci 2000 Sep. 15 (3); 154–6.
13. Zheng N, Brown MD, Brack TA, et al. Bradycardia – induced coronary angiogenesis is dependent on VEGF// Circ. Res. 1999; 85; 192–8.
Рецензия
Для цитирования:
СИСАКЯН А.С., ОГАНЯН В.А., СЕМЕРДЖЯН A.Б., ПЕТРОСЯН М.В., СИСАКЯН С.А., ГУРЕВИЧ М.А. ВЛИЯНИЕ ФАКТОРА АНГИОГЕНЕЗА НА МОРФОФУНКЦИОНАЛЬНОЕ СОСТОЯНИЕ МИОКАРДА У КРЫС ПРИ ЭКСПЕРИМЕНТАЛЬНОМ ИНФАРКТЕ МИОКАРДА. Российский кардиологический журнал. 2008;(2):63-66.
For citation:
Sisakyan A.S., Oganyan V.A., Semerdzhyan A.B., Petrosyan M.V., Sisakyan S.A., Gurevich M.A. Angiogenesis factor influence on myocardial morphology and function in rats with experimental myocardial infarction. Russian Journal of Cardiology. 2008;(2):63-66. (In Russ.)